|
Last Updated: Nov 17th, 2006 - 22:35:04 |
Latest Research
:
Pharmacology
:
Anti-Inflammatory
:
Rofecoxib
Prospective trial confirms Rofecoxib's cardiovascular risks
The trial, known as APPROVe (Adenomatous Polyp Prevention on Vioxx), was the longest test yet of Vioxx as a chemoprevention agent, and was designed to determine whether the drug could prevent the re-growth of precancerous colon polyps in people who had already had polyps removed. The prospective chemoprevention study randomized 2,586 participants from 108 centers in 29 countries to receive either 25 mgs. of Vioxx daily or a placebo drug for three years, 2001-2004. The trial was stopped September 30, 2004 - approximately two months before its planned completion.
Feb 16, 2005, 15:22
|
